by Jacob Thomas, Natural News:
-
- A new study published in Neuro-Oncology reveals that standard, aggressive treatment for slow-growing IDH-mutated gliomas causes significant, measurable cognitive decline within one year, challenging the assumption that such therapy is always beneficial.
-
- Patients receiving the standard protocol of radiotherapy and chemotherapy after surgery showed marked deterioration: 24% declined in executive function, 21% in language and 23% in memory and learning.
- The risk of cognitive damage is significantly higher for older patients and those receiving the combination of radiation and chemotherapy, as these treatments inflict collateral damage on critical brain regions like the frontal and temporal lobes.
TRUTH LIVES on at https://sgtreport.tv/
-
- The findings suggest that for these slower-progressing tumors, the rigid application of aggressive protocols may cause irreversible harm, where a more cautious, personalized approach could preserve brain function without sacrificing survival.
-
- The report calls for a paradigm shift in cancer care, emphasizing patient empowerment, informed consent about treatment trade-offs and a greater focus on root-cause mitigation and lifestyle interventions to protect brain health.
A groundbreaking study has exposed a severe and often unspoken consequence of standard brain cancer treatment: rapid, measurable cognitive decline. Published in the journal Neuro-Oncology, the research followed 127 patients with IDH-mutated gliomas, often considered “slow-growing” tumors, through surgery and subsequent guideline-based treatment. The results challenge the foundational assumption that aggressive, multimodal therapy is always in the patient’s best interest.
According to BrightU.AI‘s Enoch, IDH-mutated gliomas are a distinct subtype characterized by mutations in the IDH1 or IDH2 genes, which lead to the production of an oncometabolite (D-2-hydroxyglutarate) that alters cellular epigenetics and metabolism, resulting in a generally slower-growing tumor with a better prognosis compared to IDH-wildtype gliomas.
Of the participants, 104 received the standard protocol of radiotherapy and chemotherapy. Comprehensive cognitive testing before surgery and one year later, compared against matched controls, revealed a stark pattern of deterioration. Executive function, critical for planning, managing responsibilities and maintaining independence, declined in 24% of patients. Language function dropped in 21% and memory and learning capabilities worsened in 23%.
